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A B S T R A C T
A pooled analysis of two double-blind, multicentre, Phase III studies compared oral telithromycin
800 mg once-daily for 5 days with penicillin V 500 mg three-times-daily or clarithromycin 250 mg twice-
daily for 10 days in the treatment of Streptococcus pyogenes (group A b-haemolytic streptococcus;
GABHS) tonsillopharyngitis. Patients aged ‡ 13 years with acute GABHS tonsillopharyngitis were
randomised to receive telithromycin (n = 430), penicillin (n = 197) or clarithromycin (n = 231). Clinical
isolates of S. pyogenes (n = 590) obtained from throat swab samples on study entry were tested for their
in-vitro susceptibility to telithromycin, clarithromycin and azithromycin. Telithromycin demonstrated
in-vitro activity against the clinical isolates of S. pyogenes (MIC50 ⁄ 90 0.03 ⁄ 0.06 mg ⁄L) higher than
clarithromycin or azithromycin (MIC50 ⁄ 90 0.06 ⁄ 0.06 mg ⁄L and 0.12 ⁄ 0.25 mg ⁄L, respectively), including
erythromycin-resistant strains. At the post-therapy ⁄ test of cure (TOC) visit (days 16–23), satisfactory
bacteriological outcome was demonstrated for 88.3% (234 ⁄ 265) and 88.6% (225 ⁄ 254) of telithromycin-
and comparator-treated patients, respectively (per-protocol population). Overall, GABHS eradication
rates were 88.7% (235 ⁄ 265) for telithromycin and 89.0% (226 ⁄ 254) for comparators. The clinical cure
rates at the post-therapy ⁄TOC visit were 93.6% (248 ⁄ 265) and 90.9% (220 ⁄ 242) for telithromycin and
pooled comparators, respectively. Telithromycin was generally well-tolerated. Most adverse events
considered to be possibly related to study medication were gastrointestinal and of mild intensity.
Discontinuations as a result of adverse events were few in both treatment groups. In conclusion,
telithromycin 800 mg once-daily for 5 days was as effective as penicillin V or clarithromycin for 10 days
in the treatment of GABHS tonsillopharyngitis.
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I N T R O D U C T I O N
Acute tonsillopharyngitis is a common upper
respiratory tract infection, and is one of the most
frequent reasons for consulting a primary care
physician [1]. Most acute upper respiratory tract
infections are of viral origin and hence do not
require treatment with antibacterials [2]. How-
ever, in the case of acute tonsillopharyngitis,
c. 15% of episodes are caused by Streptococcus
pyogenes (group A b-haemolytic streptococcus;
GABHS), which is the most common bacterial
cause of the infection [2]. While this condition is
not life-threatening, morbidity such as pharyn-
geal pain and dysphagia necessitates rapid symp-
tom relief through use of appropriate antibacterials
[3]. Moreover, effective antibacterial therapy is
recommended to reduce the spread of infection
and to prevent the development of rare but
significant complications, such as acute rheumatic
fever [4].
Various antibacterial agents have proven effic-
acy against GABHS, including penicillin V,
macrolides and cephalosporins [1]. Treatment
for 10 days with oral penicillin V remains the
treatment of choice, with macrolides such as
clarithromycin and erythromycin recommended
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for patients who are allergic to penicillin [4,5].
While S. pyogenes remains fully susceptible to
penicillin V, the utility of macrolides in penicillin-
allergic patients is under threat because of the
increase in macrolide resistance among S. pyo-
genes isolates in recent years [6–11].
Bacteriological and clinical failure rates in the
region of 30% with penicillin V [12] have led to
the development of more effective agents [4].
Non-adherence to 10-day regimens is also a
common problem associated with current treat-
ment options for tonsillopharyngitis, and has
been cited as one of the factors in treatment
failure [13]. Poor adherence also seems to con-
tribute to the development and spread of anti-
bacterial resistance [14,15]. Shortening the course
of antibacterial therapy may reduce the potential
for emergence of resistant strains. Indeed, there is
a growing body of evidence that shorter courses
of non-penicillin antibiotics are effective in the
treatment of tonsillopharyngitis [16].
Telithromycin is the first of a new class of
antibacterial agents developed for clinical use—the
ketolides—that are structurally similar to the
macrolides. In-vitro studies have shown that telith-
romycin has a potent and focused spectrum of
antibacterial activity against respiratory pathogens,
including S. pyogenes [17–19]. Moreover, telithro-
mycin does not induce macrolide–lincosamide–
streptogramin (MLS) resistance in Staphylococcus
aureus, Streptococcus pneumoniae and S. pyogenes
[20]. An oral regimen of telithromycin 800 mg once-
daily has been shown in vivo to achieve and
maintain plasma [21] and tissue [22,23] concentra-
tions at or above the MIC for common respiratory
pathogens, including S. pyogenes.
In this paper, the results of two clinical trials
are combined to compare the bacteriological and
clinical efficacy and safety of telithromycin
800 mg once-daily for 5 days with treatment with
penicillin V 500 mg three-times-daily [24] (Study
3004) or clarithromycin 250 mg twice-daily [25]
(Study 3008) for 10 days in the treatment of
GABHS tonsillopharyngitis in adolescents and
adult patients. These data have been presented in
part previously [26].
P A T I E N T S A N D M E T H O D S
Two randomised (1:1), multicentre, double-blind, comparative
studies were conducted in a total of 118 centres in 12 countries
(Belgium, Canada, Czech Republic, Denmark, Finland, Ger-
many, Hungary, New Zealand, South Africa, Switzerland, UK,
USA). The studies were approved by local independent Ethics
Committees, and were conducted in accordance with the latest
revision to the Declaration of Helsinki. Written informed
consent was obtained from all patients before participation in
the studies.
Patients
Adolescent and adult patients aged ‡ 13 years were eligible for
inclusion in the studies if they had clinical signs and symp-
toms of acute GABHS tonsillopharyngitis, which included a
sore throat and one or more of the following: fever, erythema
of the uvula and pharynx or tonsils, oedema of these tissues,
exudates or cervical lymphadenopathy. In addition, patients
needed to have either a positive test result for rapid detection
of group A streptococcal antigen from a throat swab, or a
positive throat culture for GABHS.
Patients were excluded if they had an infection of the deep
tissues of the upper or sub-pharyngeal respiratory tract and its
connecting structures; were suspected to have non-streptococ-
cal or viral tonsillitis or pharyngitis; were suspected to be
chronic streptococcal carriers or to be in an environment where
reinfection was known to be occurring; had already received
treatment with penicillin V for the infection; or had been treated
with systemic or local antimicrobial agents within 7 days
before study entry. Additional exclusion criteria, including
previous or concomitant medical conditions and prohibited
medications, are detailed in previous publications [24,25].
Study design
On entry to the study (day 1), patients underwent a physical
examination including assessment of infection-related signs
and symptoms, vital signs and 12-lead electrocardiograms
(ECGs). Throat swab specimens were taken for rapid antigen
detection and microbiological culture. Blood and urine samples
were taken to determine laboratory safety parameters.
Patients were randomised to receive oral telithromycin
800 mg once-daily in the morning for 5 days, or a comparator
antimicrobial (penicillin V 500 mg three-times-daily (Study
3004) or clarithromycin 250 mg twice-daily (Study 3008)) for
10 days. Blinding was maintained by masking the tablets in
capsules and with the use of matching placebo capsules where
appropriate. Following treatment with telithromycin for
5 days, patients received a matching placebo for 5 days.
Adherence was assessed by counting unused returned study
medication at the on-therapy and end-of-therapy visits.
Patients were reassessed in the clinic at an on-therapy visit
(days 3–5), an end-of-therapy visit (days 11–13), a post-therapy
therapy ⁄ test of cure (TOC) visit (days 16–23), and a late post-
therapy (LPT) visit (days 31–45). Clinical signs and symptoms of
infection and overall clinical status or outcome were assessed at
each visit, and throat swabs for microbiological cultures, blood
samples and urine samples were taken. A physical examination
was also performed and vital signs were measured.
Assessments
In-vitro susceptibility testing and genotyping of clinical isolates
S. pyogenes isolates, cultured from throat swab samples
obtained on entry to the study, were tested for their in-vitro
susceptibility to telithromycin, clarithromycin and azithromy-
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cin. Susceptibility testing was performed initially using disk
diffusion methods at each participating laboratory, and sub-
cultures of primary isolates were retested subsequently at a
central laboratory (Clinical Microbiology Institute, Wilsonville,
OR, USA, or GR Micro Ltd, London, UK) by disk diffusion and
for MICs using National Committee for Clinical Laboratory
Standards methodology [27]. The MIC distribution of telithro-
mycin was compared with that of clarithromycin and azith-
romycin. Genotyping for the presence of erm and mef
sequences was performed on isolates of S. pyogenes that were
resistant to macrolides (erythromycin) [28].
Efficacy
The primary efficacy variable was bacteriological outcome at
the post-therapy ⁄TOC visit in the per-protocol (PP) popula-
tion. Secondary efficacy variables were bacteriological out-
come at the post-therapy ⁄TOC visit (bacteriological modified
intent-to-treat population (bmITT) population) and at the late
post-therapy visit (bmITT and PP populations), and clinical
outcome at the post-therapy ⁄TOC and late post-therapy visits
(modified intent-to-treat (mITT) and PP populations). Bac-
teriological outcome was classified as satisfactory, unsatisfac-
tory or indeterminate at the post-therapy ⁄TOC visit according
to the following definitions.
• Satisfactory: the causative pathogen was absent (eradicated)
or a new serotype of GABHS or bacterial strain was isolated,
and the subject had no signs or symptoms of active infection
(colonisation).
• Unsatisfactory: the causative pathogen was still present
(persistence) or assumed to be present (presumed persist-
ence); or the causative pathogen reappeared after eradica-
tion from the original site of infection (recurrence); or
elimination of the initial causative pathogen was followed by
replacement of a new serotype for the same organism at the
same site in the presence of signs and symptoms of infection
(reinfection).
• Indeterminate: it was not possible to categorise the microbio-
logical response, because of incomplete microbiological data,
death, withdrawal, concurrent treatment or discontinuation.
Bacteriological outcome at the late post-therapy visit was
defined as: satisfactory (bacteriological response satisfactory at
post-therapy ⁄TOC visit and no recurrence or reinfection and
no subsequent antimicrobial treatment for an infection at the
same site); unsatisfactory (bacteriological response unsatisfac-
tory at post-therapy ⁄TOC visit or recurrence or reinfection or
use of a new antimicrobial during follow-up); or indeterminate.
Clinical outcome was classified by the investigator as cure,
failure or indeterminate, according to the following defini-
tions:
• Cure: improvement, disappearance or return to preinfection
state of all infection-related signs and symptoms, without
the need for subsequent antimicrobial therapy.
• Failure: infection-related signs and symptoms remained
unchanged or worsened; or additional antimicrobial therapy
was initiated because of lack of clinical improvement; or
development of new clinical findings consistent with active
infection.
• Indeterminate: post-treatment information was missing or
there was early discontinuation of treatment for reasons that
were not drug-related.
Clinical outcome at the late post-therapy visit was defined
as: cure (cure at post-therapy ⁄TOC visit and no occurrence of a
new infection); failure (failure at post-therapy ⁄TOC visit, or
signs and symptoms of a new infection at the same site or
other relevant site leading to initiation of antimicrobial
treatment); or indeterminate.
Safety
Adverse events, as reported by patients or noted by the
investigator, were recorded throughout the study. The inves-
tigator assessed the severity of each adverse event and its
relationship to study medication. Safety was evaluated on the
basis of physical examination, vital signs, clinical laboratory
tests and 12-lead ECG.
Statistical analyses
All randomised patients with a positive rapid streptococcal
antigen test result, or positive throat culture for GABHS, who
received at least one dose of study medication were included
in the mITT population. The bmITT population included all
patients in the mITT population with a positive culture for
GABHS at the pretherapy visit.
The primary objective was to demonstrate equivalence
between telithromycin and the standard comparators in terms
of satisfactory bacteriological outcome at the post-ther-
apy ⁄TOC visit in the PP population. The PP population
included all bmITT patients except those with major protocol
violations. The secondary objective was to demonstrate equiv-
alence between telithromycin and the standard comparators in
terms of satisfactory bacteriological outcome at the post-
therapy ⁄TOC visit in the bmITT population. In addition,
clinical efficacy was assessed for the PP population. Safety was
evaluated in all patients who received at least one dose of
study medication and had at least one safety assessment after
the pre-therapy ⁄ entry visit.
A two-sided 95% confidence interval (CI) was constructed
for the difference in bacteriological outcomes between telith-
romycin and comparator treatment groups.
R E S U L T S
In total, 860 patients were randomised to receive
treatment across the two studies, 858 of whom
were evaluable in the mITT population (Table 1).
GABHS was isolated from 648 patients at pre-
therapy ⁄ entry to the study (telithromycin,
n = 325; comparators, n = 323), and these formed
Table 1. Number of patients (mITT population) and treat-
ment regimens for the two Phase III studies of telithromy-
cin 800 mg once-daily in the treatment of patients with
GABHS tonsillopharyngitis
Study
Treatment regimen
No. in mITT
populationAntibacterial Duration (days) Dosage
3004 Telithromycin 5 800 mg q.d. 198
Penicillin V 10 500 mg t.i.d. 197
3008 Telithromycin 5 800 mg q.d. 232
Clarithromycin 10 250 mg b.i.d. 231
Combined Telithromycin 5 – 430
Comparators 10 – 428
mITT, modified intent-to-treat; q.d., once-daily; t.i.d., three-times-daily; b.i.d., twice-
daily.
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the bmITT population. There were 519 patients
(telithromycin, n = 265; comparators, n = 254) in
the PP population.
Patients receiving telithromycin or a comparator
antimicrobial agent were well-matched in terms of
demographics, with a mean age of 32 years (range
13–81 years), and 512 (59%) females (Table 2). The
baseline disease characteristics were similar, but
slightly more patients in the telithromycin group
had a fever (oral temperature > 38C) compared
with those receiving comparator antibacterial
agents.
For both studies, full patient adherence over the
first 5 days of treatment was higher than for the
total 10-day duration of therapy (telithromycin,
87.9% vs. comparators, 85.7% for the first 5 days;
telithromycin, 71.9% vs. comparators, 72.9% for
the total 10-day period).
In total, 76 patients discontinued the study
medication (telithromycin, 37 (8.6%) ⁄ 430; penicil-
lin V, 18 (9.1%) ⁄ 198; clarithromycin, 21 (9.1%) ⁄
231).
Pathogens and in-vitro susceptibility to
antibacterial agents
In total, 590 isolates of S. pyogenes (isolated from
the bmITT population) were tested for their
susceptibility in vitro to telithromycin and the
macrolides, clarithromycin and azithromycin.
MIC distributions of these antibacterials are
shown in Fig. 1. The activity of telithromycin
against clinical isolates of S. pyogenes was high.
Mode MIC, MIC50 and MIC90 values were
0.015 mg ⁄L, 0.03 mg ⁄L and 0.06 mg ⁄L, respect-
ively. The in-vitro activity of telithromycin
against clinical isolates of S. pyogenes was superior
to that of both clarithromycin and azithromycin.
Mode MIC, MIC50 and MIC90 values were
0.06 mg ⁄L for clarithromycin, and 0.12 mg ⁄L,
0.12 mg ⁄L and 0.25 mg ⁄L, respectively, for azith-
romycin.
In this study, 28 isolates were erythromycin-
resistant; genotyping of 26 isolates was performed
by PCR for the presence of erm(B), erm(TR) and
mef(A) macrolide resistance sequences. Five iso-
lates were positive for erm(B) alone, nine for
erm(TR) alone, nine for mef(A) alone, and three for
both erm(B) and mef(A) (two erythromycin-resist-
ant isolates were not tested). Clarithromycin and
azithromycin MICs were ‡ 1.0 mg ⁄L (range
1–32 mg ⁄L) and ‡ 8.0 mg ⁄L (range 8–32 mg ⁄L),
respectively, for all erythromycin-resistant iso-
lates, irrespective of the resistance genotype. For
clarithromycin and azithromycin, the MIC ranges
were: erm(TR), 1–4 mg ⁄L and 16–32 mg ⁄L,
respectively; mef(A), 4–16 mg ⁄L and 8–16 mg ⁄L,
respectively; and erm(B), 8–32 mg ⁄L for both. In
contrast, 24 (87.5%) of 28 erythromycin-resistant
isolates had a telithromycin MIC £ 1.0 mg ⁄L
(range 0.015–8 mg ⁄L), including all isolates with
the erm(TR) (inducible MLS resistance) and mef(A)
Table 2. Baseline demographics and clinical characteris-
tics of patients treated with telithromycin (800 mg once-
daily) for 5 days or a comparator antibacteriala for 10 days
in patients with GABHS tonsillopharyngitis (mITT popu-
lation)
Characteristic
Number of patients (%)
Telithromycin n = 430 Comparators n = 428a
Sex
Male 171 (39.8) 175 (40.9)
Female 259 (60.2) 253 (59.1)
Mean age (years); range 31.6; 1–72 31.5; 13–81
Ethnicity
White 372 (86.5) 370 (86.4)
Black 35 (8.1) 34 (7.9)
Multiracial 19 (4.4) 21 (4.9)
Other 4 (1.0) 3 (0.7)
Smoking status
Smoker 88 (20.5) 111 (25.9)
Ex-smoker 68 (15.8) 55 (12.9)
Non-smoker 274 (63.7) 262 (61.2)
Signs and symptoms
Fever (> 38C) 98 (22.8) 78 (18.2)
Exudate 313 (72.8) 307 (71.7)
Cervical lymphadenopathy 395 (91.9) 396 (92.5)
No. GABHS tonsillopharyngitis
episodes in 12 months
0 320 (74.4) 327 (76.4)
1 62 (14.4) 54 (12.6)
> 1 48 (11.2) 47 (11.0)
History of ear-, nose- or
throat-related surgery
37 (8.6) 39 (9.1)
aPenicillin V 500 mg three-times-daily or clarithromycin 250 mg twice-daily.
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Fig. 1. MIC distributions of telithromycin, clarithromycin
and azithromycin for 590 clinical isolates of Streptococcus
pyogenes. aIsolates with MIC of 0.015 mg ⁄L (Study 3004)
and 0.016 mg ⁄L (Study 3008) combined.
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(resistance by efflux) genes. Four isolates with a
telithromycin MIC of 8.0 mg ⁄L had the erm(B)
(constitutive MLS resistance) genotype. However,
the remaining erm(B) isolate, and all isolates
harbouring erm(B) in combination with mef(A)
(3 ⁄ 3), had a telithromycin MIC £ 1.0 mg ⁄L.
Bacteriological outcome
In Study 3004, a satisfactory bacteriological
outcome was demonstrated for 84.3% of patients
treated with telithromycin and 89.1% of patients
treated with penicillin V at the post-ther-
apy ⁄TOC visit in the PP population (Table 3).
In the bmITT population, response rates were
79.7% in the telithromycin group, and 79.3% in
the penicillin V group. In Study 3008, 91.3% of
telithromycin-treated patients and 88.1% of
clarithromycin-treated patients in the PP popu-
lation had satisfactory bacteriological outcomes
at the post-therapy ⁄TOC visit (respective rates
for the bmITT population were 81.3% and
77.5%) (Table 3). Equivalence was demonstrated
between therapy with telithromycin for 5 days
and the individual comparators for 10 days
(Table 3). Similar results were observed in both
the PP and bmITT populations, and equivalence
between treatments was demonstrated at the
LPT visit (Table 3).
In Study 3004, S. pyogenes was eradicated in
85.2% (98 ⁄ 115) of telithromycin-treated patients
and 89.1% (106 ⁄ 119) of penicillin V-treated
patients at the post-therapy ⁄TOC visit (Fig. 2).
Eradication rates were 86.1% (93 ⁄ 108) and 86.5%
(96 ⁄ 111) for telithromycin- and penicillin V-trea-
ted patients, respectively, at the LPT visit. In
Study 3008, eradication rates were 91.3%
(137 ⁄ 150) in the telithromycin-treated patients
and 88.9% (120 ⁄ 135) in the clarithromycin-treated
patients at the post-therapy ⁄TOC visit, and 84.6%
(115 ⁄ 136) and 82.5% (99 ⁄ 120), respectively, at the
LPT visit (Fig. 2).
Combining the data from both studies revealed
that 88.3% of patients treated with telithromycin
had a satisfactory bacteriological outcome com-
pared with 88.6% of comparator-treated patients
at the post-therapy ⁄TOC visit (Table 3). An over-
all GABHS eradication rate of 88.7% (235 ⁄ 265)
was obtained for telithromycin and of 89.0%
(226 ⁄ 254) for pooled comparators at the post-
therapy ⁄TOC visit. Similar results were observed
at the LPT visit (Table 3; Fig. 2).
An analysis of the influence of various clinical
and demographic factors on bacteriological out-
come at the post-therapy ⁄TOC visit demonstrated
that GABHS infection in the last 12 months,
previous ear-, nose- or throat-related surgery,
gender, age and smoking status had no significant
effect on outcome in the telithromycin or com-
parator groups. Overall, the presence of cervical
lymphadenopathy or exudate did not influence
Table 3. Satisfactory bacteriological
outcome at the post-therapy ⁄ test of
cure and late post-therapy visits in
patients treated with telithromycin
(800 mg once-daily) for 5 days or a
comparator antibacterial agenta for
10 days in patients with GABHS
tonsillopharyngitis
No. of patients (%) PP No. of patients (%) bmITT
Telithromycin Comparatora 95% CI Telithromycin Comparatora 95% CI
Post-therapy, test of cure (days 16–23)
Study 3004 97 ⁄ 115 (84.3) 106 ⁄ 119 (89.1) ) 14.3; 4.8 110 ⁄ 138 (79.7) 119 ⁄ 150 (79.3) ) 9.6; 10.4
Study 3008 137 ⁄ 150 (91.3) 119 ⁄ 135 (88.1) ) 4.6; 11.0 152 ⁄ 187 (81.3) 134 ⁄ 173 (77.5) ) 5.0; 12.8
Combined 234 ⁄ 265 (88.3) 225 ⁄ 254 (88.6) ) 6.2; 5.6 262 ⁄ 325 (80.6) 253 ⁄ 323 (78.3) ) 4.2; 8.8
Late post-therapy (days 31–45)
Study 3004 89 ⁄ 108 (82.4) 94 ⁄ 111 (84.7) 13.0; 8.5 103 ⁄ 138 (74.6) 109 ⁄ 150 (72.7) ) 8.9; 12.8
Study 3008 112 ⁄ 136 (82.4) 98 ⁄ 120 (81.7) ) 9.5; 10.9 133 ⁄ 187 (71.1) 116 ⁄ 173 (67.1) ) 6.0; 14.2
Combined 201 ⁄ 244 (82.4) 192 ⁄ 231 (83.1) ) 8.0; 6.5 236 ⁄ 325 (72.6) 225 ⁄ 323 (69.7) ) 4.3; 10.2
aPenicillin V 500 mg three-times-daily or clarithromycin 250 mg twice-daily.
BmITT, bacteriological modified intent-to-treat; CI, confidence interval; PP, per protocol.
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significantly the bacteriological outcome in the
treatment groups, with eradication rates in these
subgroups being comparable to those in the total
PP population.
Clinical outcome
Clinical cure rates in patients treated with telith-
romycin were equivalent to those observed with
penicillin V and clarithromycin at both post-
therapy and late post-therapy visits (Table 4). At
the post-therapy ⁄TOC visit, clinical cure rates in
telithromycin-treated patients were 92.7–94.8%
(mean 93.6%), compared with 94.1% in penicillin
V-treated patients and 91.1% in clarithromycin-
treated patients (per-protocol). In Study 3004 at
LPT, clinical cure rates were 92.6% and 90.1% for
telithromycin- and penicillin V-treated patients,
respectively. Corresponding values in Study 3008
were 89.6% for patients treated with telithromy-
cin and 87.3% for those treated with clarithromy-
cin (Table 4). In each study, the clinical efficacy
results obtained in the mITT population con-
firmed the results obtained in the PP population.
Efficacy in patients with erythromycin-resistant
strains of GABHS
Eleven erythromycin-resistant strains of S. pyogenes
(MIC ‡ 1.0 mg ⁄L) were isolated from telithromy-
cin-treated patients in the PP population. Bacterial
eradication of erythromycin-resistant strains was
achieved in three patients at the post-therapy ⁄TOC
visit and in six patients at the LPT visit. Interest-
ingly, clinical cure was attained in ten of these
patients at the post-therapy ⁄TOC visit and in nine
patients at the LPT visit.
Four erythromycin-resistant strains of S. pyo-
genes were isolated from clarithromycin-treated
patients. Bacterial eradication of erythromycin-
resistant strains was achieved from four patients
at both the post-therapy ⁄TOC and LPT visits,
while clinical cure was attained in two of these
patients at the post-therapy ⁄TOC and LPT visits.
In total, nine erythromycin-resistant strains of S.
pyogenes were isolated from penicillin-treated
patients. Bacterial eradication and clinical cure
was achieved with eight of these strains at both
the post-therapy ⁄TOC and LPT visits.
Safety
Safety data were available for 851 of the 858
patients in the mITT population. In Study 3004,
treatment-emergent adverse events (TEAEs) were
reported by 35.4% (70 ⁄ 198) of patients treated
with telithromycin and 35.2% (69 ⁄ 196) of patients
treated with penicillin V. In Study 3008, these
values were 67.2% (154 ⁄ 229) and 57.5% (60 ⁄ 228)
for telithromycin- and clarithromycin-treated
patients, respectively.
Most of the adverse events were mild or
moderate in intensity for all treatment groups.
Diarrhoea was the most common treatment-rela-
ted adverse event in the telithromycin- and
comparator-treated patients, but caused < 1% of
patients in both groups to discontinue treatment.
Gastrointestinal adverse events (diarrhoea, nau-
sea, vomiting or gastrointestinal pain) that were
considered by the investigator to be possibly
related to treatment (and occurred in ‡ 2% of
patients) affected 22.7% (45 ⁄ 198) and 32.3%
(74 ⁄ 229) of telithromycin-treated patients in Stud-
ies 3004 and 3008, respectively. In contrast, 5.6%
(11 ⁄ 196) and 11.4% (26 ⁄ 228) of penicillin V- and
clarithromycin-treated patients, respectively,
experienced gastrointestinal adverse events. The
majority of gastrointestinal events were of mild
intensity for telithromycin-treated patients
(72 ⁄ 119; 60.5%) and comparator-treated patients
Table 4. Clinical cure rates at the
post-therapy ⁄ test of cure and late
post-therapy visits in patients trea-
ted with telithromycin (800 mg
once-daily) for 5 days or a compa-
rator antibacteriala for 10 days in
patients with GABHS
No. of patients (%) PP No. of patients (%) mITT
Telithromycin Comparatora 95% CI Telithromycin Comparatora 95% CI
Post-therapy, test of cure (days 16–23)
Study 3004 109 ⁄ 115 (94.8) 112 ⁄ 119 (94.1) ) 6.1; 7.4 170 ⁄ 198 (85.9) 169 ⁄ 197 (85.8) ) 7.3; 7.5
Study 3008 139 ⁄ 150 (92.7) 123 ⁄ 135 (91.1) ) 5.5; 8.6 193 ⁄ 232 (83.2) 192 ⁄ 231 (83.1) ) 7.2; 7.3
Combined 248 ⁄ 265 (93.63) 235 ⁄ 254 (92.5) ) 3.7; 5.8 363 ⁄ 430 (84.4) 361 ⁄ 428 (84.3) ) 5.0; 5.2
Late post-therapy (days 31–45)
Study 3004 100 ⁄ 108 (92.6) 100 ⁄ 111 (90.1) ) 5.8; 10.9 161 ⁄ 198 (81.3) 163 ⁄ 197 (82.7) ) 9.5; 6.6
Study 3008 120 ⁄ 134 (89.6) 103 ⁄ 118 (87.3) ) 96.5; 11.0 178 ⁄ 232 (76.7) 170 ⁄ 231 (73.6) ) 5.2; 11.4
Combined 220 ⁄ 242 (90.94) 203 ⁄ 229 (88.6) ) 3.6; 8.2 339 ⁄ 430 (78.8) 333 ⁄ 428 (77.8) ) 4.7; 6.8
aPenicillin V 500 mg three-times-daily or clarithromycin 250 mg twice-daily.
mITT, modified intent-to-treat; CI, confidence interval; PP, per protocol.
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(27 ⁄ 37; 73.0%). Discontinuations as a result of all
treatment-related adverse events were few and
similar in telithromycin- and comparator-treated
patients, ranging between 4.5% and 5.7%, and
3.9% and 4.1%, respectively. There were no
relevant differences between the treatment
groups in terms of clinically noteworthy abnor-
mal laboratory values. No clinically noteworthy
ECG QTc changes (QTc > 500 ms) were observed
in telithromycin- or clarithromycin-treated
patients in Study 3008.
D I S C U S S I O N
This analysis pools data from the first two studies
to report on the efficacy and safety of telithromy-
cin in the treatment of GABHS tonsillopharyngitis
in adolescent and adult patients. The results
reveal that a course of telithromycin 800 mg
once-daily for 5 days is as effective as treatment
with penicillin V (500 mg three-times-daily) or
clarithromycin (250 mg twice-daily) for 10 days
in terms of bacteriological and clinical outcome.
Penicillin V is the current treatment of choice
for GABHS tonsillopharyngitis on the basis of its
efficacy, tolerability and low cost [29]. However,
bacteriological and clinical failure rates with
penicillin therapy have been increasing steadily
since the late 1970s and are now in the region of
30% in some studies [12]. Lack of adherence to
the 10-day therapeutic regimen is thought to be
the primary cause of penicillin treatment failure
in cases of GABHS tonsillopharyngitis [12]. Alter-
native therapies include the macrolides, such as
clarithromycin, which are preferable for those
patients who are allergic to penicillin [4,5]. How-
ever, the recent rapid increase in macrolide
resistance rates among S. pyogenes isolates [6–10]
threatens the usefulness of this group of drugs in
the treatment of patients with GABHS tonsillo-
pharyngitis who are allergic to penicillin. The
limitations of current treatment options have led
to the search for effective agents whose antibac-
terial activity extends to macrolide-resistant
strains of S. pyogenes.
Telithromycin has a targeted spectrum of activ-
ity against key respiratory pathogens, including
S. pyogenes. In-vitro studies have revealed that
telithromycin has potent antibacterial activity
against S. pyogenes, including macrolide-resistant
strains [17–19], and results from these studies
confirmed that the in-vitro coverage provided
by telithromycin against clinical isolates of
S. pyogenes was superior to that observed with
either clarithromycin or azithromycin.
Macrolide resistance in S. pyogenes is mediated
principally by the products of two genes: methy-
lases encoded by the erm genes result in modifica-
tion of the 23S ribosomal RNA drug-binding site,
while the mef gene codes for an efflux pump,
resulting in an active efflux of macrolide from the
cell. Target-site modification can be expressed in
either a constitutive or inducible manner, and
confers co-resistance to all MLSB antimicrobials
[30]. The macrolide efflux system (M phenotype)
confers resistance to other 14- and 15-membered
macrolides, but not to the rest of the MLS group
[31]. The prevalence of these two resistance mech-
anisms varies geographically. Recent results from
an international surveillance study [32] indicated
that whereas the erm(TR) genotype predominated
in the USA and Canada, mef(A) was the most
common genotype among S. pyogenes isolates
worldwide. This contrasted with the distribution
of genotypes observed among S. pneumoniae iso-
lates, where in the USA most macrolide-resistant
strains were mef(A) positive, while worldwide the
erm(B) genotype predominated. In these studies,
the in-vitro coverage against clinical isolates of
S. pyogenes provided by telithromycin also exten-
ded to isolates resistant to erythromycin. Telithro-
mycin MICs varied, depending on the mechanism
of erythromycin resistance: erm(TR), 0.015–
0.06 mg ⁄L; mef(A), 0.5–1.0 mg ⁄L; and erm(B), 0.5–
8.0 mg ⁄L. In contrast, MICs were higher for
clarithromycin and azithromycin according to
genotype: erm(TR), 1–4 mg ⁄L and 16–32 mg ⁄L,
respectively; mef(A), 4–16 mg ⁄L and 8–16 mg ⁄L,
respectively; erm(B), 8–32 mg ⁄L for both.
Combining the data from the present two
studies revealed that a satisfactory bacteriological
outcome was achieved in 88.3% of patients
treated with telithromycin and 88.6% of patients
treated with penicillin V or clarithromycin at the
post-therapy ⁄TOC visit. The eradication rates for
S. pyogenes were similar in all three treatment
groups. The overall clinical cure rates were 93.6%
and 92.5% in telithromycin- and pooled compa-
rator-treated patients, respectively, at the post-
therapy ⁄TOC visit. Statistical analysis confirmed
that telithromycin and comparator antibacterial
treatment were equivalent in terms of bacterio-
logical and clinical outcome. An important con-
sideration is the stringent nature of this study
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design, with TOC assessed 16–23 days after ini-
tiation of treatment (i.e., 11–18 days after comple-
tion of telithromycin and 6–10 days after
completion of comparator antibacterials). Unlike
studies in which outcome is assessed at the end of
therapy, this approach includes early cases of
relapse and thus represents a more rigorous
evaluation of efficacy.
Among the 11 patients who received telithro-
mycin and had erythromycin-resistant GABHS
isolates, most (90.9%) achieved clinical cure com-
pared with 76.9% patients in the comparator-
treated group. Despite good clinical efficacy,
eradication of the erythromycin-resistant isolates
was lower in the telithromycin-treated group than
in the penicillin V-treated group. However, erad-
ication of these isolates was greater than with
clarithromycin, particularly at the late post-ther-
apy visit, although the numbers were too small to
allow definite conclusions to be drawn. Despite
the low numbers, the increased clinical and
bacteriological efficacy of telithromycin compared
with clarithromycin, combined with its retained
in-vitro activity against resistant mef(A)- and
erm(TR)-positive strains vs. clarithromycin and
azithromycin, suggests that telithromycin may be
a useful treatment option in geographical regions
where these genotypes predominate and when
b-lactams cannot be used.
Although the reasons for recurrence of GABHS
tonsillopharyngitis are multifactorial, non-adher-
ence plays an important role [13,29]. Often,
2–3 days after the initiation of antibacterial ther-
apy, patients will experience an improvement in
their symptoms and some forego the remaining
medicine. Poor adherence to antibacterial regi-
mens of 7–10 days contributes significantly to
treatment failure in acute respiratory tract infec-
tions [33]. Therefore, shorter treatment durations
may be associated with improved treatment
adherence. However, in order to achieve practical
pharyngeal eradication of GABHS, most oral
antibacterial agents must be administered for
10 days [1,34]. Attempts to reduce the duration
of treatment with penicillin V have led to
increased rates of bacteriological failure [34,35].
In a recent study comparing different durations of
treatment of macrolide therapy in the eradication
of group A streptococci from the throat, a 10-day
course of clarithromycin was more effective than
treatment with azithromycin for 5 days [36]. In the
present studies, patient adherence to all treat-
ments was good, with no difference between the
telithromycin and comparator groups in terms of
those patients taking at least 70% of their medi-
cation. Of note in both studies was the fact that full
adherence over the first 5 days of treatment was
higher than for the total 10-day duration of
therapy for all three treatments. The more con-
venient once-daily dosing schedule and short
treatment courses could lead to better adherence
to telithromycin regimens in the outpatient set-
ting, thereby minimising the risk of treatment
failure.
Telithromycin was generally well-tolerated in
both studies, with most adverse events being of
mild or moderate intensity. Gastrointestinal
adverse events were more common in telithro-
mycin-treated patients; however, they were not
treatment limiting. Furthermore, the number of
discontinuations caused by adverse events was
similar in patients treated with telithromycin and
comparators.
In conclusion, the ability of short-course (5-day)
treatment with telithromycin to achieve clinical
cure and bacteriological eradication rates com-
parable to those obtained with treatment with
standard comparator antibacterial agents for
10 days, with in-vitro activity improved over that
of clarithromycin and azithromycin, together with
the convenience of once-daily dosing, makes
telithromycin an attractive alternative to b-lac-
tams for the treatment of GABHS tonsillopharyn-
gitis in adolescents and adults. Improved
adherence over the first 5 days of treatment
further supports the use of an agent with a
shorter duration of treatment.
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